Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer

Contributed by: Business Wire

Logo

Tags

Other Health

Research

Pharmaceutical

Oncology

Medical Devices

Technology

Artificial Intelligence

Science

Biotechnology

Other Technology

Other Science

Health

Marion Ghibaudo

More Like This

PR Newswire associated0

Appointment of Silvère Lucquin as Chief Executive Officer of Okomera

PR Newswire associated0

Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation

Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships

Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic Appointments in France

CORRECTING and REPLACING Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care